I took a quick look at VNDA. Market cap $214M vs GERN $1.6B. Then look at the chart. GERN just went back up to a year high, while VNDA has been doing nothing but tanking- almost 50% from a year ago. Then VNDA just got bad news from the FDA about how their latest supplimental NDA for Hetlioz can't be approved in their current form. https://finance.yahoo.com/news/vanda-vnda-falls-fdas-crl-154700469.html
RN, how can you even compare these two companies. How much in revenues is expected to come in for VNDA, even if their insomnia drug is approved ? Do you realize there are other insomnia drugs out there ? GERN will have one of only two drugs in the entire world for a deadly anemia MDS(which turns into leukemia), and is expected to share a $4B+/year market with Bristol Myers drug Reblozyl by 2028. GERN by the way has around $400M in cash right now, and no debt.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.